LISPRO (lithium/proline/salicylate) News

||||||||||  LISPRO (lithium/proline/salicylate) / Alzamend Neuro
Trial completion, Trial completion date:  MAD: Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects (clinicaltrials.gov) -  Jul 20, 2023
P1/2, N=65, Completed,  Sponsor: Alzamend Neuro, Inc.
Active, not recruiting --> Completed | Trial completion date: Oct 2023 --> May 2023

||||||||||  LISPRO (lithium/proline/salicylate) / Alzamend Neuro
Enrollment closed:  MAD: Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects (clinicaltrials.gov) -  Mar 23, 2023
P1/2, N=72, Active, not recruiting,  Sponsor: Alzamend Neuro, Inc.
Active, not recruiting --> Completed | Trial completion date: Oct 2023 --> May 2023 Recruiting --> Active, not recruiting

||||||||||  LISPRO (lithium/proline/salicylate) / Alzamend Neuro
Trial completion date, Trial primary completion date:  MAD: Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects (clinicaltrials.gov) -  Jan 11, 2023
P1/2, N=72, Recruiting,  Sponsor: Alzamend Neuro, Inc.
Recruiting --> Active, not recruiting Trial completion date: May 2023 --> Oct 2023 | Trial primary completion date: Dec 2022 --> Apr 2023

||||||||||  LISPRO (lithium/proline/salicylate) / Alzamend Neuro
Enrollment change:  MAD: Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects (clinicaltrials.gov) -  Nov 1, 2022
P1/2, N=72, Recruiting,  Sponsor: Alzamend Neuro, Inc.
Trial completion date: May 2023 --> Oct 2023 | Trial primary completion date: Dec 2022 --> Apr 2023 N=40 --> 72

||||||||||  LISPRO (lithium/proline/salicylate) / Alzamend Neuro
Enrollment open:  MAD: Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects (clinicaltrials.gov) -  May 6, 2022
P1/2, N=40, Recruiting,  Sponsor: Alzamend Neuro, Inc.
N=40 --> 72 Not yet recruiting --> Recruiting

||||||||||  LISPRO (lithium/proline/salicylate) / Alzamend Neuro
New P1/2 trial:  MAD: Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects (clinicaltrials.gov) -  May 4, 2022
P1/2, N=40, Not yet recruiting,  Sponsor: Alzamend Neuro, Inc.



	Diseases Companies Products Productz Mechanisms of Action Sites